Eintrag weiter verarbeiten
Current challenges in cancer gene therapy
Gespeichert in:
Zeitschriftentitel: | Journal of Internal Medicine |
---|---|
Personen und Körperschaften: | |
In: | Journal of Internal Medicine, 242, 1997, S740, S. 109-114 |
Format: | E-Article |
Sprache: | Englisch |
veröffentlicht: |
Wiley
|
Schlagwörter: |
author_facet |
HWU, P. HWU, P. |
---|---|
author |
HWU, P. |
spellingShingle |
HWU, P. Journal of Internal Medicine Current challenges in cancer gene therapy Internal Medicine |
author_sort |
hwu, p. |
spelling |
HWU, P. 0954-6820 1365-2796 Wiley Internal Medicine http://dx.doi.org/10.1111/joim.1997.242.s740.109 <jats:p>The ability to transfer novel genes into mammalian cells has allowed us to conceive of novel strategies towards cancer therapy. Since the initial gene‐transfer clinical trial in 1989, over 300 cancer patients have been enrolled in gene therapy trials. Despite this, an NIH‐sponsored panel concluded that ‘clinical efficacy has not been definitively demonstrated at this time in any gene therapy protocol’ [1]. However, the first 8 years of gene therapy research have provided us with insights regarding the areas that require further scientific progress. For example, it is now clear that while <jats:italic>in vitro</jats:italic> assays of gene‐modified haemotopoietic progenitor cells suggest high transduction efficiencies, once these cells are infused <jats:italic>in vivo,</jats:italic> only a small percentage of circulating transduced cells can be detected. While the initial clinical studies have demonstrated that gene transfer in patients can be safe and feasible, they have also indicated that future research is necessary towards the development of improved gene transfer techniques for these approaches to be successful.</jats:p> Current challenges in cancer gene therapy Journal of Internal Medicine |
doi_str_mv |
10.1111/joim.1997.242.s740.109 |
facet_avail |
Online Free |
finc_class_facet |
Medizin |
format |
ElectronicArticle |
fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjE5OTcuMjQyLnM3NDAuMTA5 |
id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjE5OTcuMjQyLnM3NDAuMTA5 |
institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
imprint |
Wiley, 1997 |
imprint_str_mv |
Wiley, 1997 |
issn |
0954-6820 1365-2796 |
issn_str_mv |
0954-6820 1365-2796 |
language |
English |
mega_collection |
Wiley (CrossRef) |
match_str |
hwu1997currentchallengesincancergenetherapy |
publishDateSort |
1997 |
publisher |
Wiley |
recordtype |
ai |
record_format |
ai |
series |
Journal of Internal Medicine |
source_id |
49 |
title |
Current challenges in cancer gene therapy |
title_unstemmed |
Current challenges in cancer gene therapy |
title_full |
Current challenges in cancer gene therapy |
title_fullStr |
Current challenges in cancer gene therapy |
title_full_unstemmed |
Current challenges in cancer gene therapy |
title_short |
Current challenges in cancer gene therapy |
title_sort |
current challenges in cancer gene therapy |
topic |
Internal Medicine |
url |
http://dx.doi.org/10.1111/joim.1997.242.s740.109 |
publishDate |
1997 |
physical |
109-114 |
description |
<jats:p>The ability to transfer novel genes into mammalian cells has allowed us to conceive of novel strategies towards cancer therapy. Since the initial gene‐transfer clinical trial in 1989, over 300 cancer patients have been enrolled in gene therapy trials. Despite this, an NIH‐sponsored panel concluded that ‘clinical efficacy has not been definitively demonstrated at this time in any gene therapy protocol’ [1]. However, the first 8 years of gene therapy research have provided us with insights regarding the areas that require further scientific progress. For example, it is now clear that while <jats:italic>in vitro</jats:italic> assays of gene‐modified haemotopoietic progenitor cells suggest high transduction efficiencies, once these cells are infused <jats:italic>in vivo,</jats:italic> only a small percentage of circulating transduced cells can be detected. While the initial clinical studies have demonstrated that gene transfer in patients can be safe and feasible, they have also indicated that future research is necessary towards the development of improved gene transfer techniques for these approaches to be successful.</jats:p> |
container_issue |
S740 |
container_start_page |
109 |
container_title |
Journal of Internal Medicine |
container_volume |
242 |
format_de105 |
Article, E-Article |
format_de14 |
Article, E-Article |
format_de15 |
Article, E-Article |
format_de520 |
Article, E-Article |
format_de540 |
Article, E-Article |
format_dech1 |
Article, E-Article |
format_ded117 |
Article, E-Article |
format_degla1 |
E-Article |
format_del152 |
Buch |
format_del189 |
Article, E-Article |
format_dezi4 |
Article |
format_dezwi2 |
Article, E-Article |
format_finc |
Article, E-Article |
format_nrw |
Article, E-Article |
_version_ |
1792334397671735302 |
geogr_code |
not assigned |
last_indexed |
2024-03-01T14:27:59.602Z |
geogr_code_person |
not assigned |
openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Current+challenges+in+cancer+gene+therapy&rft.date=1997-07-01&genre=article&issn=1365-2796&volume=242&issue=S740&spage=109&epage=114&pages=109-114&jtitle=Journal+of+Internal+Medicine&atitle=Current+challenges+in+cancer+gene+therapy&aulast=HWU&aufirst=P.&rft_id=info%3Adoi%2F10.1111%2Fjoim.1997.242.s740.109&rft.language%5B0%5D=eng |
SOLR | |
_version_ | 1792334397671735302 |
author | HWU, P. |
author_facet | HWU, P., HWU, P. |
author_sort | hwu, p. |
container_issue | S740 |
container_start_page | 109 |
container_title | Journal of Internal Medicine |
container_volume | 242 |
description | <jats:p>The ability to transfer novel genes into mammalian cells has allowed us to conceive of novel strategies towards cancer therapy. Since the initial gene‐transfer clinical trial in 1989, over 300 cancer patients have been enrolled in gene therapy trials. Despite this, an NIH‐sponsored panel concluded that ‘clinical efficacy has not been definitively demonstrated at this time in any gene therapy protocol’ [1]. However, the first 8 years of gene therapy research have provided us with insights regarding the areas that require further scientific progress. For example, it is now clear that while <jats:italic>in vitro</jats:italic> assays of gene‐modified haemotopoietic progenitor cells suggest high transduction efficiencies, once these cells are infused <jats:italic>in vivo,</jats:italic> only a small percentage of circulating transduced cells can be detected. While the initial clinical studies have demonstrated that gene transfer in patients can be safe and feasible, they have also indicated that future research is necessary towards the development of improved gene transfer techniques for these approaches to be successful.</jats:p> |
doi_str_mv | 10.1111/joim.1997.242.s740.109 |
facet_avail | Online, Free |
finc_class_facet | Medizin |
format | ElectronicArticle |
format_de105 | Article, E-Article |
format_de14 | Article, E-Article |
format_de15 | Article, E-Article |
format_de520 | Article, E-Article |
format_de540 | Article, E-Article |
format_dech1 | Article, E-Article |
format_ded117 | Article, E-Article |
format_degla1 | E-Article |
format_del152 | Buch |
format_del189 | Article, E-Article |
format_dezi4 | Article |
format_dezwi2 | Article, E-Article |
format_finc | Article, E-Article |
format_nrw | Article, E-Article |
geogr_code | not assigned |
geogr_code_person | not assigned |
id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjE5OTcuMjQyLnM3NDAuMTA5 |
imprint | Wiley, 1997 |
imprint_str_mv | Wiley, 1997 |
institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
issn | 0954-6820, 1365-2796 |
issn_str_mv | 0954-6820, 1365-2796 |
language | English |
last_indexed | 2024-03-01T14:27:59.602Z |
match_str | hwu1997currentchallengesincancergenetherapy |
mega_collection | Wiley (CrossRef) |
physical | 109-114 |
publishDate | 1997 |
publishDateSort | 1997 |
publisher | Wiley |
record_format | ai |
recordtype | ai |
series | Journal of Internal Medicine |
source_id | 49 |
spelling | HWU, P. 0954-6820 1365-2796 Wiley Internal Medicine http://dx.doi.org/10.1111/joim.1997.242.s740.109 <jats:p>The ability to transfer novel genes into mammalian cells has allowed us to conceive of novel strategies towards cancer therapy. Since the initial gene‐transfer clinical trial in 1989, over 300 cancer patients have been enrolled in gene therapy trials. Despite this, an NIH‐sponsored panel concluded that ‘clinical efficacy has not been definitively demonstrated at this time in any gene therapy protocol’ [1]. However, the first 8 years of gene therapy research have provided us with insights regarding the areas that require further scientific progress. For example, it is now clear that while <jats:italic>in vitro</jats:italic> assays of gene‐modified haemotopoietic progenitor cells suggest high transduction efficiencies, once these cells are infused <jats:italic>in vivo,</jats:italic> only a small percentage of circulating transduced cells can be detected. While the initial clinical studies have demonstrated that gene transfer in patients can be safe and feasible, they have also indicated that future research is necessary towards the development of improved gene transfer techniques for these approaches to be successful.</jats:p> Current challenges in cancer gene therapy Journal of Internal Medicine |
spellingShingle | HWU, P., Journal of Internal Medicine, Current challenges in cancer gene therapy, Internal Medicine |
title | Current challenges in cancer gene therapy |
title_full | Current challenges in cancer gene therapy |
title_fullStr | Current challenges in cancer gene therapy |
title_full_unstemmed | Current challenges in cancer gene therapy |
title_short | Current challenges in cancer gene therapy |
title_sort | current challenges in cancer gene therapy |
title_unstemmed | Current challenges in cancer gene therapy |
topic | Internal Medicine |
url | http://dx.doi.org/10.1111/joim.1997.242.s740.109 |